More important, our study shows that in dabrafenib-resistant cells, inhibition of PTTG1 expression efficiently impairs proliferation and invasiveness, suggesting that in patients progressing on dabrafenib therapy, PTTG1 targeting, alone or in combination with BRAFi, could represent a useful strategy to control tumor growth and metastatic spreading. This evidence concerns the gene PTTG1 and neoplasm.